Total Payments
$1,205
2024 Payments
$20.11
Companies
19
Transactions
62
Medicare Patients
3,024
Medicare Billing
$440,781
Payment Breakdown by Category
Food & Beverage$1,193 (99.0%)
Education$12.17 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,193 | 61 | 99.0% |
| Education | $12.17 | 1 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $388.32 | 25 | $0 (2022) |
| Novo Nordisk Inc | $189.84 | 7 | $0 (2024) |
| GlaxoSmithKline, LLC. | $170.39 | 6 | $0 (2023) |
| Amarin Pharma Inc. | $71.44 | 3 | $0 (2020) |
| Global Blood Therapeutics, Inc. | $54.39 | 3 | $0 (2020) |
| Indivior Inc. | $47.63 | 2 | $0 (2021) |
| Orexo US, Inc. | $41.38 | 2 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $39.82 | 2 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $28.41 | 2 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $20.70 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20.11 | 1 | Novo Nordisk Inc ($20.11) |
| 2023 | $21.88 | 1 | GlaxoSmithKline, LLC. ($21.88) |
| 2022 | $72.66 | 4 | Orexo US, Inc. ($22.98) |
| 2021 | $206.60 | 8 | Novo Nordisk Inc ($145.89) |
| 2020 | $326.84 | 19 | AstraZeneca Pharmaceuticals LP ($65.53) |
| 2019 | $205.07 | 12 | AstraZeneca Pharmaceuticals LP ($104.00) |
| 2018 | $164.36 | 10 | AstraZeneca Pharmaceuticals LP ($148.12) |
| 2017 | $187.86 | 7 | GlaxoSmithKline, LLC. ($114.36) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Diabetes | ||||||
| 10/30/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: VACCINES | ||||||
| 12/19/2022 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $12.78 | General |
| Category: Obesity | ||||||
| 08/25/2022 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Neuroscience | ||||||
| 05/11/2022 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $22.98 | General |
| Category: Addiction Medicine | ||||||
| 04/07/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Respiratory | ||||||
| 11/03/2021 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: Obesity | ||||||
| 10/07/2021 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $7.74 | General |
| Category: Obesity | ||||||
| 08/13/2021 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $6.96 | General |
| Category: Obesity | ||||||
| 08/11/2021 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: OUD | ||||||
| 07/29/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Diabetes | ||||||
| 07/29/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Respiratory | ||||||
| 04/07/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: Respiratory | ||||||
| 02/11/2021 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: Respiratory | ||||||
| 12/18/2020 | Global Blood Therapeutics, Inc. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: SICKLE CELL DISEASE | ||||||
| 12/09/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/05/2020 | Ultragenyx Pharmaceutical Inc. | — | Food and Beverage | In-kind items and services | $14.07 | General |
| 12/05/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: Obesity | ||||||
| 11/25/2020 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: CNS | ||||||
| 11/16/2020 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Virology & Specialty Care | ||||||
| 11/03/2020 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: OUD | ||||||
| 10/19/2020 | GlaxoSmithKline, LLC. | ANORO ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: RESPIRATORY | ||||||
| 09/22/2020 | Merck Sharp & Dohme Corporation | ROTATEQ (Biological), PNEUMOVAX 23, VAQTA | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: VACCINE | ||||||
| 09/22/2020 | Merck Sharp & Dohme Corporation | PNEUMOVAX 23 (Biological) | Education | In-kind items and services | $12.17 | General |
| Category: VACCINE | ||||||
| 09/09/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE, SYNJARDY XR | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 506 | 1,180 | $175,542 | $64,858 |
| 2022 | 11 | 472 | 1,435 | $212,958 | $82,587 |
| 2021 | 20 | 976 | 2,461 | $406,095 | $148,771 |
| 2020 | 24 | 1,070 | 2,664 | $414,445 | $144,564 |
Total Patients
3,024
Total Services
7,740
Medicare Billing
$440,781
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 100 | 338 | $67,600 | $22,901 | 33.9% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 30 | 290 | $23,600 | $14,160 | 60.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 78 | 192 | $28,800 | $8,684 | 30.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 50 | 50 | $12,500 | $6,897 | 55.2% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 48 | 49 | $14,700 | $3,185 | 21.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 24 | 40 | $10,000 | $2,676 | 26.8% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 21 | 37 | $5,550 | $1,914 | 34.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 29 | $5,742 | $1,873 | 32.6% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 60 | 60 | $3,000 | $1,193 | 39.8% |
| 36410 | Insertion of needle into vein (3 years or older) | Office | 2023 | 39 | 49 | $2,450 | $635.04 | 25.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 14 | $1,280 | $631.80 | 49.4% |
| 81002 | Urinalysis, manual test | Office | 2023 | 25 | 32 | $320.00 | $109.12 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 114 | 483 | $96,600 | $34,693 | 35.9% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 51 | 293 | $29,020 | $14,967 | 51.6% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 36 | 112 | $16,800 | $6,679 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 40 | 62 | $18,600 | $6,169 | 33.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 41 | 41 | $10,250 | $5,795 | 56.5% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 27 | 144 | $10,800 | $5,741 | 53.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 48 | 73 | $18,250 | $5,116 | 28.0% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 37 | 131 | $6,550 | $1,635 | 25.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 16 | $3,168 | $964.48 | 30.4% |
| 36410 | Insertion of needle into vein (3 years or older) | Office | 2022 | 41 | 53 | $2,650 | $734.58 | 27.7% |
| 81002 | Urinalysis, manual test | Office | 2022 | 25 | 27 | $270.00 | $92.94 | 34.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 145 | 603 | $120,600 | $44,999 | 37.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 261 | $78,300 | $28,374 | 36.2% |
About Dr. Manish Raval, MD
Dr. Manish Raval, MD is a Internal Medicine healthcare provider based in Newburgh, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609961952.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manish Raval, MD has received a total of $1,205 in payments from pharmaceutical and medical device companies, with $20.11 received in 2024. These payments were reported across 62 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($1,193).
As a Medicare-enrolled provider, Raval has provided services to 3,024 Medicare beneficiaries, totaling 7,740 services with total Medicare billing of $440,781. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Pediatrics
- Location Newburgh, NY
- Active Since 10/03/2006
- Last Updated 09/17/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1609961952
Products in Payments
- SYMBICORT (Drug) $234.29
- RYBELSUS (Drug) $125.00
- ANORO ELLIPTA (Drug) $114.91
- BEVESPI AEROSPHERE (Drug) $76.04
- Vascepa (Drug) $71.44
- BREZTRI (Drug) $56.34
- OXBRYTA (Drug) $54.39
- SUBLOCADE (Drug) $47.63
- Saxenda (Drug) $44.73
- Zubsolv (Drug) $41.38
- SHINGRIX (Biological) $21.88
- FARXIGA (Drug) $21.65
- SPRAVATO (Drug) $20.70
- SPIRIVA (Drug) $20.54
- TOUJEO (Drug) $20.23
- Rybelsus (Drug) $20.11
- TRADJENTA (Drug) $19.28
- AJOVY (Drug) $18.40
- Xofluza (Drug) $18.04
- Fluad (Biological) $17.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Newburgh
Mohammed Allaw, M.d, M.D
Internal Medicine — Payments: $45,650
Internal Medicine $45,650
Dr. Maruthi Penumetsa, Md, MD
Internal Medicine — Payments: $42,696
Internal Medicine $42,696
Ward Neff, M.d, M.D
Internal Medicine — Payments: $9,402
Internal Medicine $9,402
Dr. Paul Feldman, Md, MD
Internal Medicine — Payments: $8,723
Internal Medicine $8,723
Uticia Belfield, M.d, M.D
Internal Medicine — Payments: $8,682
Internal Medicine $8,682
Dr. Manga Kodali, M.d, M.D
Internal Medicine — Payments: $6,603
Internal Medicine $6,603